| Prev Close | 38.41 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 14.06 / 38.56 |
| Avg Volume | 3.66M |
| Exchange | |
| Shares Outstanding | 147.18M |
| Market Cap | 5.65B |
| EPS | -0.09 |
| Div & Yield | N.A. (N.A) |
Dyax Corp. (NASDAQ:DYAX) ("Dyax") today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Dyax by Shire plc and certain other...
Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company's fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th...
The stock markets in the United States and other parts of the world declined today as investors were disappointed with the stimulus decision of the European Central Bank (ECB). Sign up for our free ne...
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Trade-Ideas LLC identified Dyax (DYAX) as a pre-market mover with heavy volume candidate
Leaders of oil producing nations begin gathering in Vienna today for the OPEC meeting.
Trade-Ideas LLC identified Dyax (DYAX) as a post-market leader candidate
Dyax Corp. (NASDAQ: DYAX) ("Dyax") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to its proposed acquisition by Shire...
Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to...
Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.
When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.
Rigrodsky & Long, P.A.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dyax Corp.
Dyax Corp. (NASDAQ:DYAX) today announced that two oral presentations describing clinical data from its DX-2930 Phase 1b study were presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Dyax...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Dyax Corp.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dyax Corp.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Dyax...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Dyax Corp.
Here are some mid-cap names with solid upside potential.
Stock futures edge lower after Monday's rally, though remain close to all-time highs.
Big investors are willing to pay a lot more for a host of companies for a multitude of different reasons, Cramer says.
The stock market in the United States gained today amid corporate transactions in the healthcare sector. Shire PLC agreed to acquire Dyan Corp. On the other hand, Pfizer was reportedly making progress...
U.S. markets ended Monday's session in the green as deal news boosted the health care sector following Shire's announcement that it would acquire drugmaker Dyax.
November extends October's stellar run in the beginning of what will be a crucial week for Federal Reserve watchers.
Stocks extend gains Monday afternoon as the health care sector rallies.
Here's a technical look at how to trade some of the most active stocks on the market right now.
The Dublin-based pharmaceutical will use the deal to bolster its rare disease drug portfolio, and says it can still afford to bid on larger target Baxalta.
